iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | BTEERegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 22.0 | 0.5 | 0.7 | -1.7 | -2.9 | |
+/-Cat | -3.9 | 9.6 | 8.6 | -0.4 | 0.8 | |
+/-B’mrk | -10.9 | 0.2 | -1.7 | -9.0 | -9.4 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
Closing Price 01/05/2024 | USD 6.09 | |
Day Change | 2.41% | |
Morningstar Category™ | Sector Equity Biotechnology | |
Volume | 453 | |
Exchange | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BDZVHG35 | |
Fund Size (Mil) 01/05/2024 | USD 493.63 | |
Share Class Size (Mil) 01/05/2024 | USD 34.66 | |
Ongoing Charge 18/04/2024 | 0.35% |
Investment Objective: iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | BTEE |
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
- - | ||
Inception Date 05/03/2018 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | BTEE | 29/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 8.60 |
Vertex Pharmaceuticals Inc | Healthcare | 8.02 |
Regeneron Pharmaceuticals Inc | Healthcare | 7.87 |
Gilead Sciences Inc | Healthcare | 7.79 |
AstraZeneca PLC ADR | Healthcare | 4.78 |
Increase Decrease New since last portfolio | ||
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | BTEE |